Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Metrics to compare | ATXI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATXIPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −0.3x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.4x | 2.3x | 2.6x | |
Price / LTM Sales | - | 2.0x | 3.2x | |
Upside (Analyst Target) | - | 170.3% | 41.2% | |
Fair Value Upside | Unlock | 22.9% | 6.2% | Unlock |